Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.45 |
| ▸ | MPL | P40238 | 3/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399327 | 0.86 | PDE2A (0.43) | MPLPDE2AADRB2 | |
| SCHEMBL4228847 | 0.86 | PDE2A (0.43) | MPLPDE2AADRB2 | |
| SCHEMBL296445 | 0.86 | PDE2A (0.43) | MPLPDE2AADRB2 | |
| SCHEMBL5019023 | 0.86 | PDE2A (0.43) | MPLPDE2AADRB2 | |
| SCHEMBL21153576 | 0.85 | MPL (0.42) | KIF11MPLSUCNR1TRPV3FFAR1 | |
| Hydrochloric Acid SCHEMBL26615659 | 0.84 | PDE2A (0.42) | MPLPDE2AADRB2 | |
| Hydrochloric Acid SCHEMBL3701319 | 0.84 | PDE2A (0.42) | MPLPDE2AADRB2 | |
| SCHEMBL7865718 | 0.83 | PDE2A (0.42) | MPLPDE2AADRB2 | |
| SCHEMBL22766122 | 0.82 | KIF11 (0.42) | KIF11MPLSUCNR1TRPV3FFAR1 | |
| SCHEMBL31030963 | 0.80 | MPL (0.55) | KIF11MPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183776-A2 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | UNIV NEW YORK (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | UNIV NEW YORK (US) | 2023-09-21 | — | — | US | disclosed |
| US-11376216-B2 | Periodontal disease therapy | NEW YORK UNIVERSITY (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200383902-A1 | PERIODONTAL DISEASE THERAPY | NEW YORK UNIVERSITY | 2020-12-10 | — | — | US | disclosed |
| WO-2019136022-A1 | PERIODONTAL DISEASE THERAPY | NEW YORK UNIVERSITY (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376216-B2 | Periodontal disease therapy | SUCNR1, SDHA, GCDH | KIF11 4617/4885MPL 1625/4885PDE2A 72/4885 |
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | SUCNR1, SYNGR2, TSPO | KIF11 4161/4885MPL 4456/4885PDE2A 4342/4885 |
| US-20200383902-A1 | PERIODONTAL DISEASE THERAPY | SUCNR1, SDHA, GCDH | KIF11 4617/4885MPL 1625/4885PDE2A 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.